Zyban online research references









  • State medicaid coverage for tobacco-dependence treatments--United States, 1998 and 2000.
  • Influence of fluoxetine on the ability of bupropion to modulate extracellular dopamine and norepinephrine concentrations in three mesocorticolimbic areas of rats.
  • Open-label pilot study of bupropion plus bromocriptine for treatment of cocaine dependence.
  • Antidepressant side effects in depression patients treated in a naturalistic setting: a study of bupropion, moclobemide, paroxetine, sertraline, and venlafaxine.
  • Interaction of dopamine D1 and NMDA receptors mediates acute clozapine potentiation of glutamate EPSPs in rat prefrontal cortex.
  • Rx drugs
  • Marked suppression of gastric ulcerogenesis and intestinal responses to stress by a novel class of drugs.
  • Bupropion inhibits nicotine-evoked (3)Hoverflow from rat striatal slices preloaded with (3)Hdopamine and from rat hippocampal slices preloaded with (3)Hnorepinephrine.
  • Adverse drug reaction update.
  • Risk factors for falls during treatment of late-life depression.
  • Zyban: a new aid to smoking cessation treatment--will it work for psychiatric patients?
  • Does insurance coverage for drug therapy affect smoking cessation?
  • Direct evidence of facilitative actions of dopamine in the medial preoptic area on reflexive and noncontact erections in male rats.
  • Endogenous and exogenous dopamine presynaptically inhibits glutamatergic reticulospinal transmission via an action of D2-receptors on N-type Ca2+ channels.
  • Bupropion enhances brain reward function and reverses the affective and somatic aspects of nicotine withdrawal in the rat.
  • Effect of bupropion on nicotine self-administration in rats.
  • Characterization of the effects of bupropion on the reinforcing properties of nicotine and food in rats.
  • Influence of complex solubility on formulations based on lambda carrageenan and basic drugs.
  • Duration of antidepressive treatments
  • Bupropion treatment of fluoxetine-resistant chronic fatigue syndrome.
  • Rx drugs
  • Bupropion is a nicotinic antagonist.
  • Successful treatment with a nicotine lozenge of smokers with prior failure in pharmacological therapy.
  • A comparison of the effects of sibutramine hydrochloride, bupropion and methamphetamine on dopaminergic function: evidence that dopamine is not a pharmacological target for sibutramine.
  • Mass spectrometric investigation of 2-aminopropiophenones and some of their metabolites.
  • Cardiovascular effects of bupropion in depressed patients with heart disease.
  • GABAergic modulation of amnesic trace reproduction by activation of the dopaminergic system
  • Antidepressant profile of bupropion and three metabolites in mice.
  • Chronic antidepressant and clonidine treatment effects on conflict behavior in the rat.
  • Effects on opioid-induced rate reductions by doxepin and bupropion.
  • Effect of bupropion on cimetidine and ranitidine absorption in rats.
  • Effects of cocaine and related drugs in nonhuman primates. III. Self-administration by squirrel monkeys.
  • Effect of dopaminergic drugs on the reserpine-induced lowering of hippocampal theta wave frequency in rats.
  • Pharmacokinetics of bupropion and metabolites in plasma and brain of rats, mice, and guinea pigs.
  • Drug coverage decisions: the role of dollars and values.
  • Differentiation of dopamine overflow and uptake processes in the extracellular fluid of the rat caudate nucleus with fast-scan in vivo voltammetry.
  • Effect of plasma from patients containing bupropion and its metabolites on the uptake of norepinephrine.
  • Striatal dopamine uptake and swim performance of the aged rat.
  • Dopamine-norepinephrine interactions in the development of hyperphagia and obesity following medial hypothalamic lesions.
  • Pharmacological significance of the species differences in bupropion metabolism.
  • Anorectic and behavioural effects of bupropion.
  • Behavioral screen for antidepressants: the effects of drugs and electroconvulsive shock on performance under a differential-reinforcement-of-low-rate schedule.
  • Activity of dopamine-containing substantia nigra neurons in freely moving cats.
  • COPD. Interventions for smoking cessation and improved ventilatory function.
  • The disposition of bupropion and its metabolites in healthy male volunteers after single and multiple doses.
  • Central effects of repeated treatment with bupropion.
  • Acute effects of antidepressants on hippocampal seizures.
  • Neurochemical and neuropharmacological investigations into the mechanisms of action of bupropion . HCl--a new atypical antidepressant agent.
  • Radioimmunoassay for bupropion in human plasma: comparison of tritiated and iodinated radioligands.
  • Bupropion's prophylactic efficacy in bipolar affective illness.
  • Metabolism and kinetics of bupropion.
  • Bupropion in Parkinson's disease.
  • Affinity changes of rat striatal dopamine receptors in vivo after acute bupropion treatment.
  • Radioimmunoassay and pharmacokinetic profile of bupropion in the dog.
  • Titer-dependent antagonism of cocaine following active immunization in rhesus monkeys.
  • Animal model of depression: tests of three structurally and pharmacologically novel antidepressant compounds.
  • Assessment of the discriminative stimulus effects of cocaine in the rat: lack of interaction with opioids.
  • Dopamine transporter mediated release of dopamine: role of chloride.
  • Regulation of dopamine receptors by bupropion: comparison with antidepressants and CNS stimulants.
  • Amphetamine and antidepressant drug effects on GABA- and NMDA-related seizures.
  • Differential regulation of dopamine transporter after chronic self-administration of bupropion and nomifensine.
  • Dopaminergic mediation of the discriminative stimulus effects of bupropion in rats.
  • The Expert Consensus Guidelines for treating depression in bipolar disorder.
  • Use of bupropion with SRIs and venlafaxine.
  • Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine.
  • Antimicrobial activity of selected non-antibiotics--activity of methotrexate against Staphylococcus aureus strains.
  • Use of bupropion SR in a pharmacist-managed outpatient smoking-cessation program.
  • Modification of norepinephrine and serotonin, but not dopamine, neuron firing by sustained bupropion treatment.
  • Serotonin-dopamine interactions in the control of conditioned reinforcement and motor behavior.







    DreamPharm: Herbal and Nutritional supplements online || Hair Million herbal formula for hair loss and hair growth || Antibiotics and prescription medications online literature ||